目的 探討都梁軟膠囊聯(lián)合佐米曲普坦治療偏頭痛的臨床療效。方法 選取2015年8月-2016年8月在開封市第二人民醫(yī)院接受治療的偏頭痛患者94例，根據(jù)患者意愿分為對照組（47例）和治療組（47例）。對照組口服佐米曲普坦片，2.5 mg/次，1次/d。治療組在對照組的基礎(chǔ)上口服都梁軟膠囊，3粒/次，3次/d。兩組患者連續(xù)治療4周。評價兩組患者臨床效果，同時比較兩組患者治療前后臨床癥狀評分和VAS評分變化。結(jié)果 治療后，對照組和治療組的總有效率分別為80.85%和95.74%，兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者頭痛發(fā)作次數(shù)、頭痛持續(xù)時間及伴隨癥狀評分均顯著下降，同組治療前后差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后治療組上述臨床癥狀改善更顯著，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組VAS評分均降低，同組治療前后差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者VAS評分降低更顯著，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 都梁軟膠囊聯(lián)合佐米曲普坦治療偏頭痛效果顯著，利于臨床癥狀的改善，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Duliang Soft Capsules combined with zolmitriptan in treatment of migraine. Methods Patients (94 cases) with migraine in Kaifeng Second People's Hospital from August 2015 to August 2016 were divided into control group (47 cases) and treatment group (47 cases) based on patients' willingness. Patients in the control group were po administered with Zolmitriptan Tablets, 2.5 mg/time, once daily. Patients in the treatment group were po administered with Duliang Soft Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 week. After treatment, the clinical efficacy was evaluated, clinical symptom score and VAS score in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.85% and 95.74%, respectively, and there was difference between two groups (P<0.05). After treatment, the headache attack frequency, headache duration, and accompanying symptom score in two groups was significantly decreased, the difference was statistically significant in the same group (P<0.05). And the improvement of these symptoms in the treatment group was significantly better than that in the control group, with significant difference between two groups (P<0.05). After treatment, VAS score in treatment group was significantly decreased, the difference was statistically significant in the same group (P<0.05). And the VAS score in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05).Conclusion Duliang Soft Capsules combined with zolmitriptan has a significant clinical effect in treatment of migraine, can improve the clinical symptoms, which has a certain clinical application value.